• Barosi, G., Bergamaschi, G., Marchetti, M., Vannucchi, A.M., Guglielmelli, P., Antonioli, E., Massa, M., Rosti, V., Campanelli, R., Villani, L., Viarengo, G., Gattoni, E., Gerli, G., Specchia, G., Tinelli, C., Rambaldi, A. & Barbui, T. for the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Italian Registry of Myelofibrosis. (2007) JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. Blood, 110, 40304036.
  • Basquiera, A.L., Soria, N.W., Ryser, R., Salguero, M., Moiraghi, B., Sackmann, F., Sturich, A.G., Borello, A., Berretta, A., Bonafe, M., Barral, J.M., Palazzo, E.D. & Garcia, J.J. (2009) Clinical significance of V617F mutation of the JAK2 gene in patients with chronic myeloproliferative disorders. Hematology, 14, 323330.
  • Frederiksen, J., Juul, K., Grande, P., Jensen, G.B., Schroeder, T.V., Tybjaerg-Hansen, A. & Nordestgaard, B.G. (2004) Methylenetetrahydrofolate reductase polymorphism (C677T), hyperhomocysteinemia, and risk of ischemic cardiovascular disease and venous thromboembolism: prospective and case-control studies from the Copenhagen City Heart Study. Blood, 104, 30463051.
  • Frikke-Schmidt, R., Nordestgaard, B.G., Stene, M.C., Sethi, A.A., Remaley, A.T., Schnohr, P., Grande, P. & Tybjaerg-Hansen, A. (2008) Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease. JAMA, 299, 25242532.
  • Jones, A.V., Chase, A., Silver, R.T., Oscier, D., Zoi, K., Wang, Y.L., Cario, H., Pahl, H.L., Collins, A., Reiter, A., Grand, F. & Cross, N.C. (2009) JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nature Genetics, 41, 446449.
  • Kilpivaara, O., Mukherjee, S., Schram, A.M., Wadleigh, M., Mullally, A., Ebert, B.L., Bass, A., Marubayashi, S., Heguy, A., Garcia-Manero, G., Kantarjian, H., Offit, K., Stone, R.M., Gilliland, D.G., Klein, R.J. & Levine, R.L. (2009) A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms. Nature Genetics, 41, 455459.
  • Landolfi, R., Cipriani, M.C. & Novarese, L. (2006) Thrombosis and bleeding in polycythemia vera and essential thrombocythemia: pathogenetic mechanisms and prevention. Best Practice Research Clinical Haematology, 19, 617633.
  • Larsen, T.S., Pallisgaard, N., Moller, M.B. & Hasselbalch, H.C. (2007) The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis–impact on disease phenotype. European Journal of Haematology, 79, 508515.
  • Martinaud, C., Brisou, P. & Mozziconacci, M.J. (2010) Is the JAK2(V617F) mutation detectable in healthy volunteers? American Journal of Hematology, 85, 287288.
  • Nielsen, C., Birgens, H.S., Nordestgaard, B.G., Kjaer, L. & Bojesen, S.E. (2011) The JAK2 V617F somatic mutation, mortality and cancer risk in the general population. Haematologica, 96, 450453.
  • Nordestgaard, B.G., Benn, M., Schnohr, P. & Tybjaerg-Hansen, A. (2007) Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA, 298, 299308.
  • Olcaydu, D., Harutyunyan, A., Jager, R., Berg, T., Gisslinger, B., Pabinger, I., Gisslinger, H. & Kralovics, R. (2009a) A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nature Genetics, 41, 450454.
  • Olcaydu, D., Skoda, R.C., Looser, R., Li, S., Cazzola, M., Pietra, D., Passamonti, F., Lippert, E., Carillo, S., Girodon, F., Vannucchi, A., Reading, N.S., Prchal, J.T., Ay, C., Pabinger, I., Gisslinger, H. & Kralovics, R.. (2009b) The ‘GGCC’ haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia vera. Leukemia, 23, 19241926.
  • Pedersen, C.B., Gotzsche, H., Moller, J.O. & Mortensen, P.B. (2006) The Danish Civil Registration System A cohort of eight million persons. Danish Medical Bulletin, 53, 441449.
  • Sidon, P., El, H.H., Dessars, B. & Heimann, P. (2006) The JAK2V617F mutation is detectable at very low level in peripheral blood of healthy donors. Leukemia, 20, 1622.
  • de Stefano, V., Fiorini, A., Rossi, E., Za, T., Farina, G., Chiusolo, P., Sica, S. & Leone, G. (2007) Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders. Journal of Thrombosis and Haemostasis, 5, 708714.
  • Storm, H.H. (1991) The Danish Cancer Registry, a self-reporting national cancer registration system with elements of active data collection. IARC Scientific Publications, 95, 220236.
  • Storm, H.H., Michelsen, E.V., Clemmensen, I.H. & Pihl, J. (1997) The Danish Cancer Registry – history, content, quality and use. Danish Medical Bulletin, 44, 535539.
  • Tefferi, A. & Vardiman, J.W. (2008) Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia, 22, 1422.
  • Tefferi, A., Skoda, R. & Vardiman, J.W. (2009) Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics. Nature Reviews Clinical Oncology, 6, 627637.
  • Thygesen, K., Alpert, J.S. & White, H.D. (2007) Universal definition of myocardial infarction. Journal of the American College of Cardiology, 50, 21732195.
  • Vannucchi, A.M., Antonioli, E., Guglielmelli, P., Longo, G., Pancrazzi, A., Ponziani, V., Bogani, C., Ferrini, P.R., Rambaldi, A., Guerini, V., Bosi, A. & Barbui, T. (2007) Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden. Leukemia, 21, 19521959.
  • World Health Organization. (1952) Third report of the Expert Committee on Health Statistics. Technical Report Series No. 53. World Health Organization: Geneva (Switzerland).
  • World Health Organization. (2004) International Classification of Diseases and Related Health Problems, 10th Revision. 2 ed. World Health Organization: Geneva (Switzerland).
  • Xu, X., Zhang, Q., Luo, J., Xing, S., Li, Q., Krantz, S.B., Fu, X. & Zhao, Z.J. (2007) JAK2(V617F): prevalence in a large Chinese hospital population. Blood, 109, 339342.
  • Zacho, J., Tybjaerg-Hansen, A., Jensen, J.S., Grande, P., Sillesen, H. & Nordestgaard, B.G. (2008) Genetically elevated C-reactive protein and ischemic vascular disease. New England Journal of Medicine, 359, 18971908.